基于下一代测序技术，使用聚（ADP-核糖）聚合酶（PARP）抑制剂对宫颈神经内分泌癌进行延长治疗。
Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.
作者信息
Rose Peter G
机构信息
Women's Health Institute, Cleveland Clinic Foundation, A-81, 9500 Euclid Ave., Cleveland, OH 44195, United States.
出版信息
Gynecol Oncol Rep. 2024 Jul 11;54:101458. doi: 10.1016/j.gore.2024.101458. eCollection 2024 Aug.
Abstract
•Next generation sequencing identified a BRCA 2 mutation in a patient with stage IVB neuroendocrine cancer of the cervix.•Treatment with rucaparib resulted in disease stabilization for 74 months.•The patient remains fully active working full time as a nurse and pursing a nurse practitioner degree.
摘要
•下一代测序在一名患有IVB期宫颈神经内分泌癌的患者中发现了BRCA 2突变。
•使用鲁卡帕尼治疗使疾病稳定了74个月。
•该患者作为护士全职工作且仍十分活跃，并正在攻读执业护士学位。
相似文献
1
Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.基于下一代测序技术，使用聚（ADP-核糖）聚合酶（PARP）抑制剂对宫颈神经内分泌癌进行延长治疗。
Gynecol Oncol Rep. 2024 Jul 11;54:101458. doi: 10.1016/j.gore.2024.101458. eCollection 2024 Aug.
2
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.基于二代测序的聚（ADP-核糖）聚合酶抑制剂治疗宫颈神经内分泌癌
Gynecol Oncol Rep. 2019 Sep 12;30:100499. doi: 10.1016/j.gore.2019.100499. eCollection 2019 Nov.
3
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.鲁卡帕利治疗复发铂类敏感型高级别卵巢癌（ARIEL2 研究第 1 部分）：一项国际多中心、开放标签、2 期临床试验。
Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.
4
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.鲁卡帕尼：一种新获批用于卵巢癌的聚（腺苷酸）核糖聚合酶（PARP）抑制剂的过去、现在与未来
Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017.
5
So-Called Serous Carcinoma of the Uterine Cervix with Mutation: Case Report and Review of the Literature.所谓的伴有突变的子宫颈浆液性癌：病例报告及文献综述
Case Rep Oncol. 2021 Dec 20;14(3):1792-1798. doi: 10.1159/000520429. eCollection 2021 Sep-Dec.
6
Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.循环肿瘤 DNA 中的回复突变可预测 PARP 抑制剂鲁卡帕利治疗高级别卵巢癌的原发性和获得性耐药。
Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.
7
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.多聚 BRCA2 突变继发于卡铂治疗后，导致 mCRPC 患者对 PARP 抑制剂芦卡帕利产生耐药：病例报告。
BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.
8
Rucaparib: a novel PARP inhibitor for advanced ovarian cancer.鲁卡帕尼：一种用于晚期卵巢癌的新型聚（ADP-核糖）聚合酶抑制剂。
Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018.
9
A profile on the FoundationFocus CDxBRCA tests.基金会焦点 CDxBRCA 测试简介。
Expert Rev Mol Diagn. 2020 Mar;20(3):285-292. doi: 10.1080/14737159.2020.1701438. Epub 2020 Feb 6.
10
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.基于基因组检测在 TRITON2 研究中鉴定出的 BRCA 突变转移性去势抵抗性前列腺癌对鲁卡帕利的反应。
Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199. Epub 2021 Oct 1.
引用本文的文献
1
Large-Cell Neuroendocrine Carcinoma of the Cervix: Case Report and Literature Review.宫颈大细胞神经内分泌癌：病例报告及文献综述
Diagnostics (Basel). 2025 Mar 19;15(6):775. doi: 10.3390/diagnostics15060775.
本文引用的文献
1
The NCI-MATCH trial: lessons for precision oncology.NCI-MATCH 试验：精准肿瘤学的经验教训。
Nat Med. 2023 Jun;29(6):1349-1357. doi: 10.1038/s41591-023-02379-4. Epub 2023 Jun 15.
2
Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.下一代测序揭示了子宫颈小细胞神经内分泌癌中的复发性体细胞突变。
Am J Surg Pathol. 2018 Jun;42(6):750-760. doi: 10.1097/PAS.0000000000001042.
3
Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions.妇科小细胞癌：病变的多面谱
Gynecol Oncol. 2014 Aug;134(2):410-8. doi: 10.1016/j.ygyno.2014.05.017. Epub 2014 May 27.
4
Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix.子宫颈小细胞癌的发病率、死亡率及预后因素
Obstet Gynecol. 2008 Jun;111(6):1394-402. doi: 10.1097/AOG.0b013e318173570b.
Zotero 插件